$Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide$

Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide

Abstract Lenalidomide is an immunomodulatory drug that is administered commonly in patients with relapsed or refractory multiple myeloma (RRMM). Eosinophils have immunological functions, for instance, in allergic diseases and asthma. The purpose of this study was to investigate the clinical signific...

Full description

Bibliographic Details
Main Authors:	Kazuhito Suzuki, Kaichi Nishiwaki, Tadahiro Gunji, Mitsuji Katori, Hidekazu Masuoka, Shingo Yano
Format:	Article
Language:	English
Published:	Wiley 2020-03-01
Series:	Cancer Medicine
Subjects:	chemotherapy hematological cancer immunology
Online Access:	https://doi.org/10.1002/cam4.2828

Similar Items

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
by: Kazuhito Suzuki, et al.
Published: (2023-11-01)

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy
by: M. Hope Robinson, et al.
Published: (2023-08-01)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
by: van de Donk NW, et al.
Published: (2012-08-01)

The role of pomalidomide in treatment of relapse and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2022-01-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
by: Meletios A. Dimopoulos, et al.
Published: (2018-12-01)

Comparison of Time to Next Treatment or Death Between Front‐Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant‐Ineligible Patients With Multiple Myeloma
by: Doris K. Hansen, et al.
Published: (2024-11-01)

Genetic mechanism for the loss of PRAME in B cell lymphomas. Reply.
by: Katsuyoshi Takata, et al.
Published: (2022-07-01)

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
by: Jani Huuhtanen, et al.
Published: (2022-09-01)

Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs
by: Janine Becker-Gotot, et al.
Published: (2022-11-01)

Herpes simplex virus lymphadenitis is associated with tumor reduction in a patient with chronic lymphocytic leukemia
by: Andres Chang, et al.
Published: (2022-09-01)

Human JAK1 gain of function causes dysregulated myelopoeisis and severe allergic inflammation
by: Catherine M. Biggs, et al.
Published: (2022-12-01)

Murine cytomegalovirus reactivation concomitant with acute graft-versus-host disease is controlled by antibodies
by: Martina Seefried, et al.
Published: (2023-03-01)

Single-cell profiling identifies impaired adaptive NK cells expanded after HCMV reactivation in haploidentical HSCT
by: Elisa Zaghi, et al.
Published: (2021-06-01)

Clinical significance of granule‐containing myeloma cells in patients with newly diagnosed multiple myeloma
by: Kazuhito Suzuki, et al.
Published: (2016-11-01)

Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
by: Maral DerSarkissian, et al.
Published: (2023-12-01)

LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE
by: Patrizia Tosi
Published: (2013-06-01)

Efficacy of Lenalidomide plus Low-Dose Dexamethasone in Thai Patients with Relapsed and/or Refractory Multiple Myeloma
by: Chutima Kunacheewa, et al.
Published: (2021-04-01)

Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma
by: Zahra Goudarzi, et al.
Published: (2024-02-01)

Occasional detection of lupus erythematosus cells in bone marrow samples: A case report
by: Safaa Jassim Mohammed
Published: (2021-07-01)

Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma
by: Annemiek Broijl, et al.
Published: (2016-04-01)

Original Versus Generic Lenalidomide in Patients with Relapsed/ Refractory Multiple Myeloma: Comparison of Efficacy and Adverse Events
by: Ali Zahit Bolaman, et al.
Published: (2021-02-01)

Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
by: Elisabetta Antonioli, et al.
Published: (2023-04-01)

PB2019: EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR-BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: M. Sasaki, et al.
Published: (2022-06-01)

LENALIDOMIDE RETREATMENT IN A PATIENT WITH RELAPSED MULTIPLE MYELOMA WHO HAD PREVIOUSLY RESPONDED TO LENALIDOMIDE
by: Vincenzo Federico
Published: (2014-08-01)

Cutaneous granuloma annulare in an adult patient with macrophage activation syndrome
by: Ruixin Deng, et al.
Published: (2023-04-01)

Yin and yang of cannabinoid CB1 receptor: CB1 deletion in immune cells causes exacerbation while deletion in non-immune cells attenuates obesity
by: Kathryn Miranda, et al.
Published: (2022-09-01)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
by: Hujun Li, et al.
Published: (2022-10-01)

Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study
by: Lee, HC, et al.
Published: (2024)

Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01)

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
by: Francesca Fazio, et al.
Published: (2022-02-01)

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
by: Jean-Luc Harousseau, et al.
Published: (2010-10-01)

Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review
by: Aneta Szudy-Szczyrek, et al.
Published: (2021-06-01)

P899: REAL-WORLD ASSESSMENT OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE OPTUM DATABASE
by: B. Dhakal, et al.
Published: (2022-06-01)

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
by: María-Victoria Mateos, et al.
Published: (2017-10-01)

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
by: Kai Rejeski, et al.
Published: (2023-07-01)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
by: Kristian T. Andersen, et al.
Published: (2020-01-01)

Investigating the role of the eosinophil in COPD
by: Camp, JR
Published: (2023)